Eli Lilly is seeing strong growth from its weight loss drugs. Investors are nervous about tariffs on drugs and weak data from ...

Orforglipron, the new weight loss pill manufactured by Eli Lilly, helped patients in a recent study lose a significant amount ...

Eli Lilly is one step closer to bringing an oral weight loss medicine to the booming obesity drug market. A clinical trial ...

Eli Lilly said it plans to submit the pill to the Food and Drug Administration for approval as a weight loss medication this ...

In the wake of this sell-off, a critical question arises about whether LLY stock represents a buying opportunity.

Eli Lilly stock beats Q2 estimates with strong sales but faces competitive risks and high valuation. Here's why investors may ...

In May, it announced it would acquire SiteOne Therapeutics, a drugmaker with a promising investigational medicine for pain.

Lilly's weight-loss medications Mounjaro and Zepbound are gaining market share on Novo's Wegovy and Ozempic, but investors ...

A legacy ranch in Jackson Hole, WY, has come onto the market, with records showing it is owned by former Eli Lilly exec Dr.

(LLY) stock plunges as Phase 3 trial data for the company's oral weight loss drug orforglipron overshadow better than ...

Eli Lilly and Company (NYSE:LLY) is one of the most profitable growth stocks to buy according to billionaires. On August 1, ...

Eli Lilly said it believes the new data bolsters the case for Mounjaro to be prescribers’ first choice for patients with Type ...